# Using Antibodies to Block IL-26 for Treating Inflammatory Diseases

> A patent for specific antibodies that block the protein IL-26 to help treat inflammatory conditions like psoriasis and Crohn's disease.

- **Patent:** US 10751416
- **Original title:** IL-26 inhibitors
- **Owner:** Centre Hospitalier Universitaire Vaudois CHUV
- **Granted:** 2020
- **Status:** Active
- **Times cited:** 1
- **Field:** biotech, pharmaceutical

## What it does

This patent describes a specific monoclonal antibody designed to bind to and neutralize a protein called Interleukin-26 (IL-26). IL-26 is a signaling molecule that can trigger inflammation in the body. By using these antibodies to block IL-26, the treatment aims to stop the inflammatory response, specifically by preventing IL-26 from causing damage independently of its usual receptor. The patent details the exact amino acid sequences (the building blocks of the antibody) required for this specific binding, ensuring the antibody targets IL-26 effectively. This could be used in patients to reduce symptoms of inflammatory diseases, such as skin thickening in psoriasis or the overproduction of other inflammatory markers like IL-6 and TNF.

## What it does NOT cover

- Does not cover any antibody that binds to IL-26 using different amino acid sequences than those specified in the claims.
- Does not cover treatments that use small molecule drugs instead of monoclonal antibodies or their fragments.
- Does not cover antibodies that bind to IL-26 but fail to inhibit its receptor-independent inflammatory function.
- Does not cover general methods of treating inflammation that do not involve the specific IL-26 inhibition described.

## The clever bit

The innovation lies in targeting the receptor-independent inflammatory function of IL-26, meaning the antibody stops the protein from causing trouble even if it is not using its standard cellular doorway to signal.

## Real-world examples

1. Experimental antibody therapies for psoriasis
2. Targeted treatments for Crohn's disease
3. Research into rheumatoid arthritis biologics

## Why it matters

Inflammatory diseases like psoriasis and Crohn's are often treated with broad-spectrum immunosuppressants that can have significant side effects. By targeting a specific protein like IL-26, this approach offers a more precise way to calm the immune system. This patent provides the intellectual property foundation for developing a targeted therapy that could potentially offer better outcomes for patients with chronic autoimmune conditions.

## Frequently asked questions

### What does Using Antibodies to Block IL-26 for Treating Inflammatory Diseases cover?

A patent for specific antibodies that block the protein IL-26 to help treat inflammatory conditions like psoriasis and Crohn's disease.

### Who owns patent US 10751416?

Centre Hospitalier Universitaire Vaudois CHUV owns this patent, granted in 2020.

### When does this patent expire?

This patent is expected to expire on August 25, 2040, when the invention enters the public domain.

### What is patent US 10751416 cited by?

This patent has been cited by 1 later patents that build on its ideas.

### What problem does this patent solve?

Inflammatory diseases like psoriasis and Crohn's are often treated with broad-spectrum immunosuppressants that can have significant side effects. By targeting a specific protein like IL-26, this approach offers a more precise way to calm the immune system. This patent provides the intellectual property foundation for developing a targeted therapy that could potentially offer better outcomes for patients with chronic autoimmune conditions.

### What does this patent NOT cover?

Does not cover any antibody that binds to IL-26 using different amino acid sequences than those specified in the claims.

**Full plain-English explainer:** https://patentbrief.org/patent/us/10751416/tagrisso-osimertinib

**Original patent:** https://patents.google.com/patent/US10751416

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._